ERBB2 and breast carcinoma: Recently, it has been found to have promising effects in the DESTINY-BreastO4 phase 3 trial in which 555 adult patients were matriculated with inoperable or metastatic HER2-Low Breast Cancer and the results revealed significantly longer progression-free survival (PFS) of 9.9 months and overall survival of 23.4 months [9].